What does “Phesgo D1” mean in the USA?
“Phesgo D1” usually refers to the Day 1 dosing visit/infusion date for Phesgo (pertuzumab + trastuzumab) in the treatment cycle. In the USA, that Day 1 date is not a single fixed calendar day; it depends on when your treatment cycle starts and how your clinician schedules each dose.
When is the first (Day 1) Phesgo dose given in the USA?
In typical scheduling, Day 1 is the start of the Phesgo cycle and is the first dose given at the beginning of treatment or at the beginning of a new cycle, after prescription and treatment start.
If you mean “when will Phesgo be available/eligible for use on Day 1 in the USA” (for example, at launch or after a regulatory step), the provided information doesn’t specify a “Day 1” launch date.
Could you mean a “D1” timing used in clinical trials or a specific label section?
Some people use “D1” to refer to trial day timing (Day 1) rather than clinic dosing. That depends on the specific study protocol or on how a prescriber is documenting administrations.
Quick clarification to get you the exact date
Can you tell me which one you’re asking about?
- Day 1 of your treatment cycle (i.e., when your first dose is scheduled), or
- Day 1 timing in a specific clinical trial/protocol, or
- A USA launch/approval “Day 1” (regulatory start date) for Phesgo?
If you share the context you’re looking at (trial name, document, or screenshot wording), I can match the correct “D1” interpretation and timing.